Navigation Links
Alimera Sciences Reports First Quarter 2013 Financial Results
Date:5/9/2013

stor inquiries:For press inquiries:John Mills, ICR

Katie Brazel, Fleishman-Hillardfor Alimera Sciences

for Alimera Sciences 310-954-1105

404-739-0150John.Mills@ICRINC.com

Katie.Brazel@fleishman.com 

Non-GAAP Financial Measures Alimera believes the metric "adjusted net loss" and "adjusted net loss per common share" are useful financial measures for investors in evaluating Alimera's performance for the periods presented. Adjusted net loss and adjusted net loss per common share exclude changes in fair value of derivative warrant liability, a non-cash expense.  These metrics, however, are not measures of financial performance under accounting principles generally accepted in the United States (GAAP) and should not be considered a substitute for net loss or net loss per common share in accordance with GAAP and may not be comparable to similarly titled measures reported by other companies. Alimera's management believes that adjusted net loss and adjusted net loss per common share are useful supplements for it and investors to Alimera's GAAP financial information because these measures exclude a non-cash expense which management believes is not reflective of Alimera's operating results due its dependence on the price of Alimera's common stock.  These non-GAAP financial measures also facilitates management's internal comparison to Alimera's historical financial performance and the financial performance of other companies. However, non-GAAP financial measures should only be read in conjunction with financial information reported under GAAP when understanding Alimera's operating performance.  For a reconciliation of net loss to adjusted net loss and net loss per common share to adjusted net loss per common share, see the table below.

Forward Looking StatementsThis press release contains "forward-looking statements," w
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alimera Sciences Secures $20 Million Debt Facility
2. Alimera Sciences To Release First Quarter Fiscal Year 2013 Financial Results
3. Alimera Sciences Reports Fourth Quarter 2012 Financial Results
4. Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results
5. Alimera Sciences Participating in Credit Suisse London One-on-One Healthcare Conference
6. Alimera Sciences Names European Management Team
7. Alimera Sciences To Present At Credit Suisse 2012 Healthcare Conference
8. Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference
9. Sangamo BioSciences Reports First Quarter 2013 Financial Results
10. Instrumentation Laboratory Awarded Massachusetts Life Sciences Center Tax Incentive
11. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
(Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: